

CORRESPONDENCE

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

TO THE EDITOR:

Qatar had a first wave of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March through June 2020, after which approximately 40% of the population had detectable antibodies against SARS-CoV-2. The country subsequently had two back-to-back waves from January through May 2021, triggered by the introduction of the B.1.1.7 (or alpha) and B.1.351 (or beta) variants.¹ This created an epidemiologic opportunity to assess reinfections.

Using national, federated databases that have captured all SARS-CoV-2-related data since the onset of the pandemic (Section S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org), we investigated the risk of severe disease (leading to acute care hospitalization), critical disease (leading to hospitalization in an intensive care unit [ICU]), and fatal disease caused by reinfections as compared with primary infections in the national cohort of 353,326 persons with polymerase-chain-reaction (PCR)-confirmed infection between February 28, 2020, and April 28, 2021, after exclusion of 87,547 persons with a vaccination record. Primary infection was defined as the first PCR-positive swab. Reinfection was defined as the first PCR-positive swab obtained at least 90 days after the primary infection. Persons with reinfection were matched to those with primary infection in a 1:5 ratio according to sex, 5-year age group, nationality, and calendar week of the PCR test date (Fig. S1 and Table S1 in the Supplementary Appendix). Classification of severe, critical, and fatal Covid-19 followed World Health Organization guidelines, and assessments were made by trained medical personnel through individual chart reviews.

December 23, 2021

N Engl J Med 2021; 385:2487-2489 DOI: 10.1056/NEJMc2108120 Metrics

NEJM CareerCenter



Of 1304 identified reinfections, 413 (31.7%) were caused by the B.1.351 variant, 57 (4.4%) by the B.1.1.7 variant, 213 (16.3%) by "wild-type" virus, and 621 (47.6%) were of unknown status (Section S1 in the Supplementary Appendix). For reinfected persons, the median time between first infection and reinfection was 277 days (interquartile range, 179 to 315). The odds of severe disease at reinfection were 0.12 times (95% confidence interval [CI], 0.03 to 0.31) that at primary infection (Table 1). There were no cases of critical disease at reinfection and 28 cases at primary infection (Table S3), for an odds ratio of 0.00 (95% CI, 0.00 to 0.64). There

Disease Outcome®	Reinfection)	Primary Infection†	Odds Ratio (95% CI		
	no. of persons with outcome/no. of persons with infection that was not seven, critical, or fatal				
Severe disease	4/1300	158/6095	0.12 (0.03-0.31)		
Critical disease	0/1300	28/6095	0.00 (0.00-0.64)		
Fatal disease	0/1300	7/6095	0.00 (0.00-2.57)		
Severe, critical, or fatal disease	4/1300	193/6095	0.10 (0.03-0.25)		
Severe disease, critical disease, and fi for classifying severe acute respiratory 2019 (Covid-19)-related dearth. Reinfections were matched with up to dar week of polymerase-chain-reaction matched to five or fewer persons with	y syndrome coronavirus 2 (five primary infections acc n testing. The final sample	SARS-CoV-2) infection severi rording to sex, 5-year age gro	ty and coronavirus disea up, nationality, and cale		

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections in the Population of Qatar.

were no cases of death from Covid-19 at reinfection and 7 cases at primary infection, resulting in an odds ratio of 0.00 (95% CI, 0.00 to 2.57). The odds of the composite outcome of severe, critical, or fatal disease at reinfection were 0.10 times (95% CI, 0.03 to 0.25) that at primary infection. Sensitivity analyses were consistent with these results (Table S2).

Reinfections had 90% lower odds of resulting in hospitalization or death than primary infections. Four reinfections were severe enough to lead to acute care hospitalization. None led to hospitalization in an ICU, and none ended in death. Reinfections were rare and were generally mild, perhaps because of the primed immune system after primary infection.

In earlier studies, we assessed the efficacy of previous natural infection as protection against reinfection with SARS-CoV-2^{2,3} as being 85% or greater. Accordingly, for a person who has already had a primary infection, the risk of having a severe reinfection is only approximately 1% of the risk of a previously uninfected person having a severe primary infection. It needs to be determined whether such protection against severe disease at reinfection lasts for a longer period, analogous to the immunity that develops against other seasonal "common-cold" coronaviruses,⁴ which elicit short-term immunity against mild reinfection but longer-term immunity against more severe illness with reinfection. If this were the case with SARS-CoV-2, the virus (or at least the variants studied to date) could adopt a more benign pattern of infection when it becomes endemic.⁴

Laith J. Abu-Raddad, Ph.D. Hiam Chemaitelly, M.Sc. Weill Cornell Medicine–Qatar, Doha, Qatar lja2002@qatar-med.cornell.edu

PHYSICIAN JOBS	JANUARY 1, 2022
Chiefs / Directors / Dept. Heads Chief Medical Officer of Home Therapies N	Florida Jeeded
Pathology Staff Pathologist - Plainview & Syosset Hos Health)	New York pital (Northwell
Psychiatry Outpatient Psychiatrist	Torrance, California
Chiefs / Directors / Dept. Heads Novant Health Medical Group is seeking B Pediatric Physicians	North Carolina C/BE FM, IM, or
Family Medicine Primary Care Physician - Corning, CA	Corning, California
Radiology Radiologist - Sonora, CA	Sonora, California



\rightarrow

 $\leftarrow \rightarrow$

ORIGINAL ARTICLE DEC 22, 2021

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb and Others

Roberto Bertollini, M.D., M.P.H. Ministry of Public Health, Doha, Qatar

for the National Study Group for COVID-19 Epidemiology

Supported by the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar; the Ministry of Public Health; Hamad Medical Corporation; and Sidra Medicine. The Qatar Genome Program supported the viral genome sequencing.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on November 24, 2021, at NEJM.org.

Members of the National Study Group for COVID-19 Epidemiology are listed in the Supplementary Appendix, available with the full text of this letter at NEJM.org.



Supplementary Material

Supplementary Appendix	PDF	511KB
Disclosure Forms	PDF	139KB

More about GLOBAL HEALTH

More from the week of December 23, 2021

PERSPECTIVE **EDITORIAL** CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL Audio Interview: A Potential New Agent to Treat Covid-19 Case 39-2021: A 26-Year-Old Woman with Respiratory Failure and Altered Mental Status D Redesign E.J. Rubin, L.R. Baden, and S. Morrissey

A. Kadar and Others

Relief in Sight — Estimated Savings under Medicare Part

S.B. Dusetzina

ORIGINAL ARTICLE DEC 23, 2021

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

R. Arbel and Others

ORIGINAL ARTICLE DEC 23, 2021

Protection against Covid-19 by BNT162b2 Booster across Age Groups

Y. M. Bar-On and Others

Tap into groundbreaking research and clinically relevant insights

SUBSCRIBE \rightarrow

Already a subscriber? Sign In or Renew

JOURNAL of		NIN Grag + Marsa +		A Sprie Crute annue Basterer	
	9	JOURNAL & MEDICINE		Includes and Edition	
Augustermen Imm Reinsteinen is Gemeil Helication Genes Gar Thospheren (J. Application Help) A. Stepatrani, J. Annie, and A.S. Koudhain Mithelingen chomment (Hinter - Hin Hinter Annedhinas, Mitestan Guest, and Hearen Kaley With Exerces), J.S. Sank, and U.J. Willie	0.0403 metros par logo Cantonia Badag Sara a logo Tan U. 547 metros de Canton Sector M. Canto a Canton Sector M. Canto a Canton Sector M. Canto Spices Matthew M. Academia (Spices and Mathhemas	* ********	rttet stammer, avteet conte	State and the second se	
Initial Control State (Control State) Initial Control State) Initial Control State (Control State) Initial Control State) Initial Control State Control State (Control State) Control State) Initial Control State Contrel Control State Control State Control State Cont	WTM: Lards and MJ, Sand One could be have a second wysetting eventses, experiment in J. Winner with a Powert Efficient A. Winner with a Powert Efficient A. Bay and (Inter- second and Sand A. Bay and (Inter- bulence in Novie C. Sta- Tem Studiership Primary Ease — WerGen Wate We Ne Sec 1,5. Approximated MJ, Harved		3 differing participants Multime feeting in many particular with Recognitive data and a second second second and analysis of the second second second second and second second second second second second the second second second second second second and second second second second second second second and second second second second second second second and second second second second second second second second and second second second second second second second second and second s		C 1.000
Burding of Characteristics Burding cases and Quality in the Comparison Burding of Institute Burding of Characteristics Burding of Char	EXCLUDE LAS SUCCES TO SUS SUS TO SUS SUS SUS SUS SUS SUS SUS SUS	Effectiveness of Mass Ora Cholera Vaccination in Beira, Mozambique	al Grand Control Contr		
	1007 (04/14/14) #05/(4) 050(#100			A Higher alfillion principal with all sends the study approximation of industry and interconnected with type principal distribution of the type principal distribution of the type principal distribution.	Ocal Cholera Vaccination in Beina, Morambique Recursting of States Recursting of States
				•	

▲ ВАСК ТО ТОР

ARTICLE CATEGORIES	RESOURCES	ABOUT US	SUBSCRIPTIONS	STAY CONNECTED	FOLLOW US
Research	Authors & Reviewers	About NEJM	Subscribe	Email Alerts	Facebook
Reviews	Submit a Manuscript	Products & Services	Renew	Create Account	y Twitter
Clinical Cases	Subscribers	Editors & Publishers	Activate Subscription	Apps	@ Instagram
Perspective	Institutions	Advertising Policies	Create Account	NEJM CareerCenter	YouTube
Commentary	Media	Contact Us	Manage Account	Podcasts	in LinkedIn
Other	Advertisers	Accessibility	Pay Bill	RSS Feed	
Browse all Articles	Agents	FAQs	Special Content	Remote Access	
Current Issue	Permissions	Help			
Issue Index	Reprints	Site Feedback			
	NEJM CareerCenter				

JOURNALS The New England Journal of Medicine NEJM Catalyst Innovations in Care Delivery NEJM Evidence

Copyright © 2022 Massachusetts Medical Society. All rights reserved. Electronic ISSN 1533-4406. Print ISSN 0028-4793. The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy



THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising.

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our <u>Cookie Information</u> page.